Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 11.440
Filter
1.
Front Cell Infect Microbiol ; 14: 1401462, 2024.
Article in English | MEDLINE | ID: mdl-39091675

ABSTRACT

Introduction: Bacterial urinary tract infections (UTI) are among the most common infectious diseases worldwide. The rise of multidrug-resistant (MDR) uropathogenic Escherichia coli (UPEC) UTI cases is a significant threat to healthcare systems. Several probiotic bacteria have been proposed as an alternative to combat MDR UTI. Lactic acid bacteria in the genus Limosilactobacillus are some of the most studied and used probiotics. However, strain-specific effects play a critical role in probiotic properties. L. reuteri KUB-AC5 (AC5), isolated from the chicken gut, confers antimicrobial and immunobiotic effects against some human pathogens. However, the antibacterial and immune modulatory effects of AC5 on UPEC have never been explored. Methods: Here, we investigated both the direct and indirect effects of AC5 against UPEC isolates (UTI89, CFT073, and clinical MDR UPEC AT31) in vitro. Using a spot-on lawn, agar-well diffusion, and competitive growth assays, we found that viable AC5 cells and cell-free components of this probiotic significantly reduced the UPEC growth of all strains tested. The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC. Results and discussion: Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. Pretreatment of UPEC-infected murine macrophage RAW264.7 cells with viable AC5 (multiplicity of infection, MOI = 1) for 24 hours enhanced macrophage-killing activity and increased proinflammatory (Nos2, Il6, and Tnfa) and anti-inflammatory (Il10) gene expression. These findings indicate the gut-derived AC5 probiotic could be a potential urogenital probiotic against MDR UTI.


Subject(s)
Limosilactobacillus reuteri , Macrophages , Probiotics , Uropathogenic Escherichia coli , Probiotics/pharmacology , Uropathogenic Escherichia coli/drug effects , Uropathogenic Escherichia coli/immunology , Limosilactobacillus reuteri/physiology , Animals , Mice , Macrophages/immunology , Macrophages/microbiology , Humans , Urothelium/microbiology , Urinary Tract Infections/microbiology , Urinary Tract Infections/prevention & control , Cell Line , Escherichia coli Infections/microbiology , Escherichia coli Infections/prevention & control , RAW 264.7 Cells , Epithelial Cells/microbiology , Chickens , Bacterial Adhesion/drug effects
3.
BMC Infect Dis ; 24(1): 662, 2024 Jul 02.
Article in English | MEDLINE | ID: mdl-38956542

ABSTRACT

BACKGROUND: Infections due to Citrobacter species are increasingly observed in hospitalized patients and are often multidrug-resistant. Yet, the magnitude and burden of Citrobacter spp. resistance in the hospital setting have not been reported. We aimed to evaluate the epidemiology of Citrobacter spp. infections among hospitalized patients, their main resistance patterns and Citrobacter spp. involvement in hospital outbreaks. METHODS: We conducted a systematic review and meta-analysis of published literature (PROSPERO registration Jan-2023, CRD42023390084). We searched Embase, Medline and grey literature for studies on hospitalized patients diagnosed with Citrobacter spp. infections, and nosocomial outbreaks due to Citrobacter spp. published during the years 2000-2022. We included observational, interventional, surveillance studies and outbreak reports. Outcomes of interest were the frequency of Citrobacter spp. infections among hospitalized patients and 3rd generation cephalosporin and/or carbapenem resistance percentages in these infections. We used random-effects models to generate pooled outcome estimates and evaluated risk of bias and quality of reporting of outbreaks. RESULTS: We screened 1609 deduplicated publications, assessed 148 full-texts, and included 41 studies (15 observational, 13 surveillance and 13 outbreak studies). Citrobacter spp. urinary tract- and bloodstream infections were most frequently reported, with Citrobacter freundii being the main causative species. Hospital-acquired infection occurred in 85% (838/990) of hospitalized patients with Citrobacter infection. After 2010, an increasing number of patients with Citrobacter spp. infections was reported in observational studies. Pooled frequency estimates for Citrobacter spp. infections could not be generated due to lack of data. The pooled prevalence of ESBL and carbapenemase producers among Citrobacter isolates were 22% (95%CI 4-50%, 7 studies) and 18% (95%CI 0-63%, 4 studies), respectively. An increased frequency of reported Citrobacter outbreaks was observed after 2016, with an infection/colonization ratio of 1:3 and a case-fatality ratio of 7% (6/89 patients). Common outbreak sources were sinks, toilets, contaminated food and injection material. Implemented preventive measures included environmental cleaning, isolation of positive patients and reinforcement of hand hygiene. Only seven out of 13 outbreaks (54%) were definitively controlled. CONCLUSION: This review highlights the clinical importance of endemic and epidemic Citrobacter spp. in healthcare settings. As an emerging, multidrug­resistant nosocomial pathogen it requires heightened awareness and further dedicated surveillance efforts.


Subject(s)
Citrobacter , Cross Infection , Enterobacteriaceae Infections , Humans , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/microbiology , Citrobacter/isolation & purification , Cross Infection/epidemiology , Cross Infection/microbiology , Hospitalization/statistics & numerical data , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Disease Outbreaks , Drug Resistance, Multiple, Bacterial , Urinary Tract Infections/epidemiology , Urinary Tract Infections/microbiology
4.
BMC Med Genomics ; 17(1): 183, 2024 Jul 09.
Article in English | MEDLINE | ID: mdl-38982318

ABSTRACT

BACKGROUND AND PURPOSE: The association of water loading with several infections remains unclear. Observational studies are hard to investigate definitively due to potential confounders. In this study, we employed Mendelian randomization (MR) analysis to assess the association between genetically predicted whole body water mass (BWM) and several infections. METHODS: BWM levels were predicted among 331,315 Europeans in UK Biobank using 418 SNPs associated with BWM. For outcomes, we used genome-wide association data from the UK Biobank and FinnGen consortium, including sepsis, pneumonia, intestinal infections, urinary tract infections (UTIs) and skin and soft tissue infections (SSTIs). Inverse-variance weighted MR analyses as well as a series of sensitivity analyses were conducted. RESULTS: Genetic prediction of BWM is associated with an increased risk of sepsis (OR 1.34; 95% CI 1.19 to 1.51; P = 1.57 × 10- 6), pneumonia (OR: 1.17; 95% CI 1.08 to 1.29; P = 3.53 × 10- 4), UTIs (OR: 1.26; 95% CI 1.16 to 1.37; P = 6.29 × 10- 8), and SSTIs (OR: 1.57; 95% CI 1.25 to 1.96; P = 7.35 × 10- 5). In the sepsis and pneumonia subgroup analyses, the relationship between BWM and infection was observed in bacterial but not in viral infections. Suggestive evidence suggests that BWM has an effect on viral intestinal infections (OR: 0.86; 95% CI 0.75 to 0.99; P = 0.03). There is limited evidence of an association between BWM levels and bacteria intestinal infections, and genitourinary tract infection (GUI) in pregnancy. In addition, MR analyses supported the risk of BWM for several edematous diseases. However, multivariable MR analysis shows that the associations of BWM with sepsis, pneumonia, UTIs and SSTIs remains unaffected when accounting for these traits. CONCLUSIONS: In this study, the causal relationship between BWM and infectious diseases was systematically investigated. Further prospective studies are necessary to validate these findings.


Subject(s)
Bacterial Infections , Genome-Wide Association Study , Mendelian Randomization Analysis , Polymorphism, Single Nucleotide , Humans , Bacterial Infections/genetics , Female , Risk Factors , Male , Urinary Tract Infections/genetics , Urinary Tract Infections/microbiology , Sepsis/genetics , Sepsis/microbiology
5.
J Infect Dev Ctries ; 18(6): 937-942, 2024 Jun 30.
Article in English | MEDLINE | ID: mdl-38990999

ABSTRACT

INTRODUCTION: Invasive device-associated nosocomial infections commonly occur in intensive care units (ICUs). These infections include intravascular catheter-related bloodstream infection (CRBSI), ventilator-associated pneumonia (VAP), and catheter-associated urinary tract infection (CAUTI). This study aimed to evaluate the factors associated with invasive device-associated nosocomial infections based on the underlying diseases of the patients and antibiotic resistance profiles of the pathogens causing the infections detected in the ICU in our hospital over a five-year period. METHODOLOGY: Invasive device-associated infections (CRBSI, VAP, and CAUTI) were detected retrospectively by the laboratory- and clinic-based active surveillance system according to the criteria of the US Centers for Disease Control and Prevention (CDC) in patients hospitalized in the ICU of the tertiary hospital between 1 January 2018 and 30 June 2023. RESULTS: A total of 425 invasive device-associated nosocomial infections and 441 culture results were detected (179 CRBSI, 176 VAP, 70 CAUTI). Out of them, 57 (13.4%) patients had hematological malignancy, 145 (34.1%) had solid organ malignancy, and 223 (52.5%) had no histopathologic diagnosis of any malignancy. An increase in extended-spectrum beta lactamase (ESBL) and carbapenem resistance in pathogens was detected during the study period. CONCLUSIONS: Antibiotic resistance of the Gram-negative bacteria associated with invasive device-associated infections increased during the study period. Antimicrobial stewardship will reduce rates of nosocomial infections, reduce mortality, and shorten hospital stay. Long-term catheterization and unnecessary antibiotic use should be avoided.


Subject(s)
Catheter-Related Infections , Cross Infection , Intensive Care Units , Pneumonia, Ventilator-Associated , Humans , Male , Retrospective Studies , Female , Cross Infection/microbiology , Cross Infection/epidemiology , Middle Aged , Catheter-Related Infections/microbiology , Catheter-Related Infections/epidemiology , Aged , Pneumonia, Ventilator-Associated/microbiology , Pneumonia, Ventilator-Associated/epidemiology , Adult , Urinary Tract Infections/microbiology , Urinary Tract Infections/epidemiology , Anti-Bacterial Agents/therapeutic use , Tertiary Care Centers/statistics & numerical data , Aged, 80 and over
6.
Medicine (Baltimore) ; 103(27): e38726, 2024 Jul 05.
Article in English | MEDLINE | ID: mdl-38968512

ABSTRACT

Urinary tract infection (UTI) is a highly prevalent infection that can affect individuals of all ages, posing a significant risk to global health in terms of both morbidity and mortality. The emergence of multidrug-resistant bacteria adds to the complexity of this public health issue. There is limited data on the current study area. Therefore, this study aimed to determine the bacterial profiles, antibiotic susceptibility patterns, and associated factors of UTIs among symptomatic university students at Haramaya University, Eastern Ethiopia from May 10 to June 15, 2021. A cross-sectional study was conducted among 281 Haramaya University students. A systematic random sampling technique was used to select the study participants. Data were collected using a self-administered questionnaire. Ten to 15 mL of midstream urine samples were collected aseptically from patients. Standard microbiological techniques were used for bacterial identifications and drug susceptibility testing. The association between dependent and independent variables was determined by the logistics regression model. Variables with a P-value of <.05 were considered statistically significant. The overall prevalence of UTI among university students was 18.1% (95% confidence interval [CI]: 13.5-23.1). The most frequently isolated bacteria were Escherichia coli (33.3%) and Staphylococcus epidermidis (29.4%). Gram-negative bacteria demonstrated high resistance against ceftazidime (100%), penicillin (96%), ampicillin (92%), and tetracycline (71%). Similarly, gram-positive bacteria exhibited significant resistance to ceftazidime (100%) and ampicillin (81%). Multidrug-resistant isolates constituted an overall prevalence of 35 (68.6%) (95% CI: 63.6-73.6). Furthermore, year of study (adjusted odds ratios [AOR] = 2.66; 95% CI: 1.23-5.76), history of UTI (AOR = 2.57; 95% CI: 1.10-6.00), and sexual activity (AOR = 0.08; 95% CI: 0.02-0.39) were identified as factors. In this study, university students exhibited a higher prevalence of UTI compared to previous studies conducted in Africa. The most commonly identified bacteria causing UTIs were E coli, followed by S epidermidis. Factors such as the year of the study, presence of flank pain, history of previous UTIs, and frequency of sexual activity were found to be associated with UTIs. All the isolates have acquired resistance to the majority of commonly prescribed antibiotics. It is crucial to regularly monitor UTIs and the proliferation of antibiotic-resistant bacteria among university students.


Subject(s)
Anti-Bacterial Agents , Microbial Sensitivity Tests , Students , Urinary Tract Infections , Humans , Ethiopia/epidemiology , Urinary Tract Infections/microbiology , Urinary Tract Infections/epidemiology , Urinary Tract Infections/drug therapy , Cross-Sectional Studies , Male , Female , Young Adult , Students/statistics & numerical data , Universities , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Adult , Prevalence , Adolescent , Drug Resistance, Multiple, Bacterial , Risk Factors
7.
Investig Clin Urol ; 65(4): 378-390, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38978218

ABSTRACT

PURPOSE: To investigate urine microbiome differences among healthy women, women with recurrent uncomplicated cystitis (rUC), and those with sporadic/single uncomplicated cystitis (sUC) to challenge traditional beliefs about origins of these infections. MATERIALS AND METHODS: Patients who underwent both conventional urine culture and next-generation sequencing (NGS) of urine were retrospectively reviewed. Symptom-free women with normal urinalysis results as a control group were also studied. Samples were collected via transurethral catheterization. RESULTS: In the control group, urine microbiome was detected on NGS in 83.3%, with Lactobacillus and Prevotella being the most abundant genera. The sensitivity of urine NGS was significantly higher than that of conventional urine culture in both the sUC group (91.2% vs. 32.4%) and the rUC group (82.4% vs. 16.4%). In urine NGS results, Enterobacterales, Prevotella, and Escherichia/Shigella were additionally found in the sUC group, while the recurrent urinary tract infection (rUTI)/rUC group exhibited the presence of Lactobacillus, Prevotella, Enterobacterales, Escherichia/Shigella, and Propionibacterium. Moreover, distinct patterns of urine NGS were observed based on menopausal status and ingestion of antibiotics or probiotics prior to NGS test sampling. CONCLUSIONS: Urine microbiomes in control, sUC, and rUTI/rUC groups exhibited distinct characteristics. Notably, sUC and rUC might represent entirely separate pathological processes, given their distinct urine microbiomes. Consequently, the use of urine NGS might be essential to enhancing sensitivity compared to conventional urine culture in both sUC and rUTI/rUC groups.


Subject(s)
Cystitis , Microbiota , Recurrence , Humans , Female , Cystitis/microbiology , Cystitis/urine , Retrospective Studies , Middle Aged , Adult , Urine/microbiology , Republic of Korea , High-Throughput Nucleotide Sequencing , Acute Disease , Urinary Tract Infections/microbiology , Aged , Clinical Relevance
8.
PLoS One ; 19(7): e0307544, 2024.
Article in English | MEDLINE | ID: mdl-39052658

ABSTRACT

Extraintestinal pathogenic Escherichia coli (ExPEC), especially uropathogenic E. coli (UPEC) are responsible for urinary tract infections (UTIs), while diarrheagenic E. coli (DEC) cause foodborne illnesses. These pathogenic E. coli are a serious threat to human health and a public concern worldwide. However, the evidence on pork E. coli (PEC) harboring UPEC virulence-associated genes is currently limited. Therefore, this study aimed to determine the phylogroups, virulence genes, and their association between PEC and UPEC from UTI patients. In this study, 330 E. coli were obtained from archived stock culture isolated from pork (PEC; n = 165) and urine of patients with UTIs (UPEC; n = 165) during 2014-2022. Phylogroups, UPEC- and diarrheagenic E. coli (DEC) associated virulence genes were assessed using PCR assays. The results showed that phylogroups A (50.3%), and B1 (32.1%) were commonly found among PEC whereas phylogroups B2 (41.8%), and C (25.5%) were commonly detected in the UPEC. PEC and UPEC carried similar virulence-associated genes with different percentages. The most frequent UPEC virulence-associated gene among UPEC, and PEC strains was fimH, (93.3%, and 92.1%), followed by iucC (55.2%, and 12.7%), papC (21.8%, and 4.2%), afaC (22.4%, and 0%), hlyCA (17%, and 0.6%), cnf (16.4%, and 0.6%), and sfa/focDE (8.5%, and 4.8%). Additionally, 6 of 27 UPEC virulence-associated gene patterns were found in both PEC and UPEC strains regardless of phylogroups. Furthermore, the DEC virulence-associated genes were found in only 3 strains, one from PEC harboring eae, and two from UPEC carried fimH-bfpA or afaC-CVD432 indicating hybrid strains. Cluster analysis showed a relationship between PEC and UPEC strains and demonstrated that PEC harboring UPEC virulence-associated genes in pork may be associated with UPEC in humans. Food safety and hygiene practices during pork production chain are important procedures for minimizing cross-contamination of these strains that could be transmitted to the consumers.


Subject(s)
Escherichia coli Infections , Phylogeny , Urinary Tract Infections , Virulence Factors , Urinary Tract Infections/microbiology , Humans , Thailand/epidemiology , Animals , Escherichia coli Infections/microbiology , Escherichia coli Infections/epidemiology , Swine , Virulence Factors/genetics , Virulence/genetics , Escherichia coli Proteins/genetics , Escherichia coli/genetics , Escherichia coli/pathogenicity , Escherichia coli/isolation & purification , Escherichia coli/classification , Uropathogenic Escherichia coli/genetics , Uropathogenic Escherichia coli/pathogenicity , Uropathogenic Escherichia coli/isolation & purification , Uropathogenic Escherichia coli/classification , Genetic Variation
9.
Diagn Microbiol Infect Dis ; 110(1): 116439, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39024934

ABSTRACT

We evaluated the DxU 850m Iris Urine Microscopy analyzer as a screening tool for excluding negative urine samples (n = 1337). At a cutoff of 103 colony counts·mL-1, sensitivity was 55.1 %, specificity 68.6 %. The DxU 850m Iris does not offer acceptable prediction of culture-negative urine samples at the tested cutoff.


Subject(s)
Microscopy , Sensitivity and Specificity , Urinalysis , Urine , Humans , Microscopy/methods , Urinalysis/methods , Urinalysis/instrumentation , Urine/microbiology , Urinary Tract Infections/diagnosis , Urinary Tract Infections/microbiology , Automation, Laboratory/methods
10.
Int J Mol Sci ; 25(14)2024 Jul 19.
Article in English | MEDLINE | ID: mdl-39063167

ABSTRACT

Urine pH reflects the functional integrity of the body and may influence the virulence of uropathogenic Escherichia coli and Klebsiella pneumoniae, the main causes of urinary tract infections (UTIs). This study evaluated the effects of acidic pH on the pathogenicity of uropathogenic E. coli and K. pneumoniae strains, in vitro and in vivo. Four uropathogenic E. coli and four K. pneumoniae strains were used. Biofilm formation, growth competition indices, motility, and adhesion and invasion of human renal cells were analyzed in media with acidic, neutral, and alkaline pH. A murine lower UTI model was used, with urine adjusted to acidic, neutral, or alkaline pH. At acidic pH, E. coli and K. pneumoniae exhibited higher bacterial concentrations in the kidneys and systemic symptoms, including bacteremia. Alkaline urine pH did not affect bacterial concentrations of any strain. In mice with UTIs caused by E. coli Nu14 and K. pneumoniae HUVR42 and acidic urine pH, histopathological studies of the kidneys showed acute inflammation affecting the urothelium and renal parenchyma, which are traits of acute pyelonephritis. These results indicate that acidic pH could increase the pathogenicity of E. coli and K. pneumoniae in murine models of lower UTI, promoting renal infection and acute inflammation.


Subject(s)
Escherichia coli , Kidney , Klebsiella Infections , Klebsiella pneumoniae , Urinary Tract Infections , Klebsiella pneumoniae/pathogenicity , Hydrogen-Ion Concentration , Animals , Mice , Urinary Tract Infections/microbiology , Urinary Tract Infections/pathology , Kidney/microbiology , Kidney/pathology , Humans , Escherichia coli/pathogenicity , Klebsiella Infections/microbiology , Klebsiella Infections/pathology , Escherichia coli Infections/microbiology , Escherichia coli Infections/pathology , Biofilms/growth & development , Female , Virulence , Disease Models, Animal , Uropathogenic Escherichia coli/pathogenicity , Pyelonephritis/microbiology , Pyelonephritis/pathology
11.
Microb Pathog ; 193: 106769, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38955237

ABSTRACT

The bacterium Escherichia coli is one of the main causes of urinary tract infections. The formation of bacterial biofilms, especially associated with the use of urinary catheters, contributes to the establishment of recurrent infections and the development of resistance to treatment. Strains of E. coli that produce extended-spectrum beta-lactamases (ESBL) have a greater ability to form biofilms. In addition, there is a lack of drugs available in the market with antibiofilm activity. Promethazine (PMZ) is an antihistamine known to have antimicrobial activity against different pathogens, including in the form of biofilms, but there are still few studies of its activity against ESBL E. coli biofilms. The aim of this study was to evaluate the antimicrobial activity of PMZ against ESBL E. coli biofilms, as well as to assess the application of this drug as a biofilm prevention agent in urinary catheters. To this end, the minimum inhibitory concentration and minimum bactericidal concentration of PMZ in ESBL E. coli strains were determined using the broth microdilution assay and tolerance level measurement. The activity of PMZ against the cell viability of the in vitro biofilm formation of ESBL E. coli was analyzed by the MTT colorimetric assay and its ability to prevent biofilm formation when impregnated in a urinary catheter was investigated by counting colony-forming units (CFU) and confirmed by scanning electron microscopy (SEM). PMZ showed bactericidal activity and significantly reduced (p < 0.05) the viability of the biofilm being formed by ESBL E. coli at concentrations of 256 and 512 µg/ml, as well as preventing the formation of biofilm on urinary catheters at concentrations starting at 512 µg/ml by reducing the number of CFUs, as also observed by SEM. Thus, PMZ is a promising candidate to prevent the formation of ESBL E. coli biofilms on abiotic surfaces.


Subject(s)
Anti-Bacterial Agents , Biofilms , Escherichia coli , Microbial Sensitivity Tests , Promethazine , Urinary Catheters , beta-Lactamases , Biofilms/drug effects , Biofilms/growth & development , Promethazine/pharmacology , Escherichia coli/drug effects , beta-Lactamases/metabolism , Urinary Catheters/microbiology , Anti-Bacterial Agents/pharmacology , Humans , Urinary Tract Infections/microbiology , Microbial Viability/drug effects , Escherichia coli Infections/microbiology , Escherichia coli Infections/drug therapy
12.
Microb Pathog ; 193: 106789, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38972365

ABSTRACT

Urinary tract infections (UTIs) by Uropathogenic Escherichia coli (UPEC) are a significant health concern, especially due to the increasing prevalence of antibiotic resistance. This study focuses on isolating and characterizing bacteriophages specific to UPEC strains isolated from UTI samples. The isolated phages were assessed for their ability to target and lyse UPEC in vitro, focusing on their efficacy in disrupting biofilms, a key virulence factor contributing to UTI recurrence and antibiotic resistance. The morphological structure observed by TEM belongs to Myoviridae, the phage exhibited icosahedral symmetry with a long non-constricting tail, the approximate measurement of the phage head was 39 nm in diameter, and the phage tail was 105.317 nm in length. One-step growth experiments showed that the latent period was approximately 20 min, followed by a rise period of 40 min, and a growth plateau was reached within 20 min and the burst size observed was 26 phages/infected bacterial cells. These phages were capable of killing cells within the biofilms, leading to a reduction in living cell counts after a single treatment. This study highlights the potential of phages to play a significant role in disrupting, inactivating, and destroying Uropathogenic Escherichia coli (UPEC) biofilms. Such findings could be instrumental in developing treatment strategies that complement antibiotics and disinfectants. The phage-antibiotic synergistic activity was compared to have the possibility to facilitate the advancement of focused and enduring alternatives to traditional antibiotic therapies for UTIs.


Subject(s)
Anti-Bacterial Agents , Bacteriophages , Biofilms , Escherichia coli Infections , Urinary Tract Infections , Uropathogenic Escherichia coli , Biofilms/drug effects , Biofilms/growth & development , Urinary Tract Infections/microbiology , Uropathogenic Escherichia coli/drug effects , Uropathogenic Escherichia coli/virology , Anti-Bacterial Agents/pharmacology , Humans , Escherichia coli Infections/microbiology , Bacteriophages/isolation & purification , Bacteriophages/physiology , Phage Therapy , Myoviridae/isolation & purification , Myoviridae/physiology , Drug Synergism , Microbial Sensitivity Tests
13.
J Med Case Rep ; 18(1): 326, 2024 Jul 17.
Article in English | MEDLINE | ID: mdl-39014508

ABSTRACT

BACKGROUND: Escherichia coli is a major human pathogen responsible for a broad range of clinical illnesses. It has been linked to endemic and epidemic nosocomial diseases caused by multidrug-resistant pathogens in Sudan as well as throughout the globe. CASE PRESENTATION: A 76-year-old African woman arrived at Saad Rashwan Medical Centre complaining of backaches and discomfort during urination. Throughout the preceding 5 years, the patient had recurrent urinary tract infections. Following overnight incubation at 37 °C, Escherichia coli was found in her midstream urine specimen on cysteine lactose electrolyte deficient agar media. Minimum inhibitory concentration (colorimetric/turbidimetric method) was employed to test a wide range of antimicrobial drugs against this bacterial strain, and the results revealed significant multidrug resistance. QIAamp® DNA Mini Kit was used to obtain DNA Template from the purified Escherichia coli (Qiagen, Hilden, Germany). The bacterial whole-genome sequence was done by Novogene company (Hong Kong) using Illumina HiSeq 2500 (Illumina, San Diego, CA, USA), followed by whole genome reconstructions, and identification of antibiotic-resistant genes. Phylogenetic analysis revealed that our strain was related to the Escherichia coli DSM30083 ( genome sequence ID: CP033092.2) from the USA. Our strain possessed the following antimicrobial-resistant genes: aminoglycoside (kdpE, baeR, cpxA, aadA5), nitroimidazole (msbA), phosphonic acid (mdtG), tetracycline (emrY), macrolide, penam, tetracycline, (evgA, TolC, H-NS), fluoroquinolone, cephalosporin, glycylcycline, penam, tetracycline, rifamycin, phenicol antibiotic, disinfecting agents and antiseptics (acrB; marA), sulfonamide (sul1), macrolide (Mrx), cephalosporin, penam (CTX-M-15), carbapenem, cephalosporin, and penam (OXA-1). CONCLUSION: This study found that the isolated Escherichia coli strain had varied antimicrobial resistance genes on the basis of whole-genome sequencing and phenotypic resistance analyses. Whole-genome sequencing is critical for control and preventative methods to battle the growing threat of antimicrobial resistance. A larger investigation is recommended for improved generalization of results.


Subject(s)
Drug Resistance, Multiple, Bacterial , Escherichia coli Infections , Escherichia coli , Immunocompromised Host , Urinary Tract Infections , Whole Genome Sequencing , Humans , Urinary Tract Infections/microbiology , Urinary Tract Infections/drug therapy , Female , Aged , Drug Resistance, Multiple, Bacterial/genetics , Escherichia coli Infections/drug therapy , Escherichia coli Infections/microbiology , Escherichia coli/genetics , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Microbial Sensitivity Tests , Phylogeny
14.
Microb Drug Resist ; 30(7): 304-313, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38949898

ABSTRACT

Little is known about the characteristics of uropathogenic Escherichia coli (UPEC) associated with recurrent urinary tract infections (RUTIs). The present study aimed to analyze the phenotypic antimicrobial resistance of recurrent UPEC isolates attributable to either relapse or reinfection. A total of 140 E. coli strains were isolated from 70 outpatients with RUTIs. All isolates were analyzed by random amplified polymorphic DNA-polymerase chain reaction to evaluate genetic similarity between the first and second isolates. We found that 64.2% (45/70) of outpatients had a relapse with the primary infecting E. coli strain and 35.7% (25/70) had reinfection with a new E. coli strain. Compared with reinfecting strains, relapse UPEC isolates exhibited much higher antimicrobial resistance; 89% of these isolates were multidrug-resistant and 46.6% were extended-spectrum ß-lactamase producers. Our study provides evidence that RUTIs are mainly driven by the persistence of the original strain in the host (relapses) despite appropriate antibiotic treatments, and only RUTIs attributed to relapses seem to favor multidrug resistance in UPEC isolates.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Multiple, Bacterial , Escherichia coli Infections , Microbial Sensitivity Tests , Recurrence , Urinary Tract Infections , Uropathogenic Escherichia coli , Humans , Urinary Tract Infections/microbiology , Urinary Tract Infections/drug therapy , Uropathogenic Escherichia coli/drug effects , Uropathogenic Escherichia coli/genetics , Uropathogenic Escherichia coli/isolation & purification , Anti-Bacterial Agents/pharmacology , Escherichia coli Infections/microbiology , Escherichia coli Infections/drug therapy , Drug Resistance, Multiple, Bacterial/genetics , Female , Male , Middle Aged , Adult , beta-Lactamases/genetics , Aged , Random Amplified Polymorphic DNA Technique
15.
Antimicrob Resist Infect Control ; 13(1): 72, 2024 Jul 06.
Article in English | MEDLINE | ID: mdl-38971782

ABSTRACT

BACKGROUND: Before the COVID-19 pandemic there has been a constant increase in antimicrobial resistance (AMR) of Escherichia coli, the most common cause of urinary tract infections and bloodstream infections. The aim of this study was to investigate the impact of the COVID-19 pandemic on extended-spectrum ß-lactamase (ESBL) production in urine and blood E. coli isolates in Finland to improve our understanding on the source attribution of this major multidrug-resistant pathogen. METHODS: Susceptibility test results of 564,233 urine (88.3% from females) and 23,860 blood E. coli isolates (58.8% from females) were obtained from the nationwide surveillance database of Finnish clinical microbiology laboratories. Susceptibility testing was performed according to EUCAST guidelines. We compared ESBL-producing E. coli proportions and incidence before (2018-2019), during (2020-2021), and after (2022) the pandemic and stratified these by age groups and sex. RESULTS: The annual number of urine E. coli isolates tested for antimicrobial susceptibility decreased 23.3% during 2018-2022 whereas the number of blood E. coli isolates increased 1.1%. The annual proportion of ESBL-producing E. coli in urine E. coli isolates decreased 28.7% among males, from 6.9% (average during 2018-2019) to 4.9% in 2022, and 28.7% among females, from 3.0 to 2.1%. In blood E. coli isolates, the proportion decreased 32.9% among males, from 9.3 to 6.2%, and 26.6% among females, from 6.2 to 4.6%. A significant decreasing trend was also observed in most age groups, but risk remained highest among persons aged ≥ 60 years. CONCLUSIONS: The reduction in the proportions of ESBL-producing E. coli was comprehensive, covering both specimen types, both sexes, and all age groups, showing that the continuously increasing trends could be reversed. Decrease in international travel and antimicrobial use were likely behind this reduction, suggesting that informing travellers about the risk of multidrug-resistant bacteria, hygiene measures, and appropriate antimicrobial use is crucial in prevention. Evaluation of infection control measures in healthcare settings could be beneficial, especially in long-term care.


Subject(s)
COVID-19 , Escherichia coli Infections , Escherichia coli , Urinary Tract Infections , beta-Lactamases , Humans , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Escherichia coli/enzymology , Finland/epidemiology , COVID-19/epidemiology , Female , Escherichia coli Infections/epidemiology , Escherichia coli Infections/microbiology , Male , Urinary Tract Infections/microbiology , Urinary Tract Infections/epidemiology , Middle Aged , beta-Lactamases/metabolism , beta-Lactamases/biosynthesis , Aged , Adult , Adolescent , Young Adult , Child , Infant , Child, Preschool , Aged, 80 and over , Microbial Sensitivity Tests , SARS-CoV-2 , Infant, Newborn , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Bacteremia/epidemiology , Bacteremia/microbiology , Drug Resistance, Multiple, Bacterial , Pandemics
16.
Front Cell Infect Microbiol ; 14: 1414188, 2024.
Article in English | MEDLINE | ID: mdl-38979511

ABSTRACT

In Escherichia coli, the disaccharide trehalose can be metabolized as a carbon source or be accumulated as an osmoprotectant under osmotic stress. In hypertonic environments, E. coli accumulates trehalose in the cell by synthesis from glucose mediated by the cytosolic enzymes OtsA and OtsB. Trehalose in the periplasm can be hydrolyzed into glucose by the periplasmic trehalase TreA. We have previously shown that a treA mutant of extraintestinal E. coli strain BEN2908 displayed increased resistance to osmotic stress by 0.6 M urea, and reduced production of type 1 fimbriae, reduced invasion of avian fibroblasts, and decreased bladder colonization in a murine model of urinary tract infection. Since loss of TreA likely results in higher periplasmic trehalose concentrations, we wondered if deletion of otsA and otsB genes, which would lead to decreased internal trehalose concentrations, would reduce resistance to stress by 0.6 M urea and promote type 1 fimbriae production. The BEN2908ΔotsBA mutant was sensitive to osmotic stress by urea, but displayed an even more pronounced reduction in production of type 1 fimbriae, with the consequent reduction in adhesion/invasion of avian fibroblasts and reduced bladder colonization in the murine urinary tract. The BEN2908ΔtreAotsBA mutant also showed a reduction in production of type 1 fimbriae, but in contrast to the ΔotsBA mutant, resisted better than the wild type in the presence of urea. We hypothesize that, in BEN2908, resistance to stress by urea would depend on the levels of periplasmic trehalose, but type 1 fimbriae production would be influenced by the levels of cytosolic trehalose.


Subject(s)
Fimbriae, Bacterial , Osmoregulation , Trehalose , Urinary Bladder , Urinary Tract Infections , Animals , Trehalose/metabolism , Mice , Urinary Bladder/microbiology , Fimbriae, Bacterial/metabolism , Fimbriae, Bacterial/genetics , Urinary Tract Infections/microbiology , Escherichia coli Infections/microbiology , Escherichia coli Proteins/metabolism , Escherichia coli Proteins/genetics , Escherichia coli/metabolism , Escherichia coli/genetics , Disease Models, Animal , Female , Osmotic Pressure , Extraintestinal Pathogenic Escherichia coli/metabolism , Extraintestinal Pathogenic Escherichia coli/genetics , Urea/metabolism , Trehalase/metabolism , Trehalase/genetics , Gene Deletion , Glucose/metabolism
17.
J Appl Microbiol ; 135(7)2024 Jul 02.
Article in English | MEDLINE | ID: mdl-38991984

ABSTRACT

AIMS: We aimed to identify mechanisms underlying the tolerance of Proteus mirabilis-a common cause of catheter associated urinary tract infection-to the clinically used biocides chlorhexidine (CHD) and octenidine (OCT). METHODS AND RESULTS: We adapted three clinical isolates to grow at concentrations of 512 µg ml-1 CHD and 128 µg ml-1 OCT. Genetic characterization and complementation studies revealed mutations inactivating the smvR repressor and increasing smvA efflux expression were associated with adaptation to both biocides. Mutations in mipA (encoding the MltA interacting protein) were less prevalent than smvR mutations and only identified in CHD adapted populations. Mutations in the rppA response regulator were exclusive to one adapted isolate and were linked with reduced polymyxin B susceptibility and a predicted gain of function after biocide adaptation. Biocide adaptation had no impact on crystalline biofilm formation. CONCLUSIONS: SmvR inactivation is a key mechanism in both CHD and OCT tolerance. MipA inactivation alone confers moderate protection against CHD, and rppA showed no direct role in either CHD or OCT susceptibility.


Subject(s)
Chlorhexidine , Imines , Proteus mirabilis , Pyridines , Proteus mirabilis/drug effects , Proteus mirabilis/genetics , Proteus mirabilis/physiology , Chlorhexidine/pharmacology , Imines/pharmacology , Pyridines/pharmacology , Microbial Sensitivity Tests , Humans , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Biofilms/drug effects , Biofilms/growth & development , Proteus Infections/microbiology , Mutation , Drug Resistance, Bacterial/genetics , Anti-Infective Agents, Local/pharmacology , Disinfectants/pharmacology , Catheter-Related Infections/microbiology , Urinary Tract Infections/microbiology
18.
Rev Assoc Med Bras (1992) ; 70(6): e20240045, 2024.
Article in English | MEDLINE | ID: mdl-39045962

ABSTRACT

OBJECTIVE: The objective of this study was to assess the clinical and uterine cervix characteristics of patients displaying vaginal discharge with positive results for Mycoplasma sp. and/or Ureaplasma spp. METHODS: An analytical cross-sectional study involving women aged 18-45 years was conducted. Microbiological assessments included Ureaplasma and Mycoplasma cultures, as well as human papillomavirus hybrid capture using ecto and endocervix swabs. All tests were two-tailed, and significance was set at p<0.05. RESULTS: Among 324 women, Ureaplasma prevalence was 17.9%, and Mycoplasma prevalence was 3.1%. The Ureaplasma-positive group exhibited a higher frequency of urinary tract infections (39.1 vs. 19%, p=0.002) and human papillomavirus (39.7 vs. 12.8%, p≤0.001) compared with controls. The Mycoplasma-positive group showed a higher frequency of non-contraceptive use compared with controls (66.2 vs. 30.0%, p=0.036). Abnormal colposcopic findings were more prevalent in the Mycoplasma/Ureaplasma-positive group than in controls (positive: 65% vs. control: 35%, p=0.001). Pap smear findings did not differ between the groups. CONCLUSION: Ureaplasma spp. was associated with urinary tract infections and human papillomavirus, while the presence of Mycoplasma sp. was linked to reduced contraceptive use. When analyzing both pathogens together, a higher frequency of abnormal colposcopic findings was observed, with no difference in cytological findings in the positive group.


Subject(s)
Cervix Uteri , Mycoplasma Infections , Mycoplasma , Ureaplasma Infections , Ureaplasma , Humans , Female , Adult , Ureaplasma Infections/microbiology , Ureaplasma Infections/epidemiology , Cross-Sectional Studies , Mycoplasma Infections/epidemiology , Mycoplasma Infections/microbiology , Ureaplasma/isolation & purification , Young Adult , Middle Aged , Adolescent , Cervix Uteri/microbiology , Cervix Uteri/pathology , Mycoplasma/isolation & purification , Vaginal Discharge/microbiology , Prevalence , Papillomavirus Infections/microbiology , Urinary Tract Infections/microbiology , Urinary Tract Infections/epidemiology , Brazil/epidemiology , Vaginal Smears
19.
Proc Natl Acad Sci U S A ; 121(29): e2400666121, 2024 Jul 16.
Article in English | MEDLINE | ID: mdl-38976738

ABSTRACT

Urinary tract infection (UTI) commonly afflicts people with diabetes. This augmented infection risk is partly due to deregulated insulin receptor (IR) signaling in the kidney collecting duct. The collecting duct is composed of intercalated cells (ICs) and principal cells (PCs). Evidence suggests that ICs contribute to UTI defenses. Here, we interrogate how IR deletion in ICs impacts antibacterial defenses against uropathogenic Escherichia coli. We also explore how IR deletion affects immune responses in neighboring PCs with intact IR expression. To accomplish this objective, we profile the transcriptomes of IC and PC populations enriched from kidneys of wild-type and IC-specific IR knock-out mice that have increased UTI susceptibility. Transcriptomic analysis demonstrates that IR deletion suppresses IC-integrated stress responses and innate immune defenses. To define how IR shapes these immune defenses, we employ murine and human kidney cultures. When challenged with bacteria, murine ICs and human kidney cells with deregulated IR signaling cannot engage central components of the integrated stress response-including activating transcriptional factor 4 (ATF4). Silencing ATF4 impairs NFkB activation and promotes infection. In turn, NFkB silencing augments infection and suppresses antimicrobial peptide expression. In diabetic mice and people with diabetes, collecting duct cells show reduced IR expression, impaired integrated stress response engagement, and compromised immunity. Collectively, these translational data illustrate how IR orchestrates collecting duct antibacterial responses and the communication between ICs and PCs.


Subject(s)
Mice, Knockout , Receptor, Insulin , Urinary Tract Infections , Uropathogenic Escherichia coli , Animals , Humans , Mice , Escherichia coli Infections/immunology , Escherichia coli Infections/metabolism , Escherichia coli Infections/microbiology , Immunity, Innate , Kidney/metabolism , Kidney Tubules, Collecting/metabolism , Mice, Inbred C57BL , Receptor, Insulin/metabolism , Signal Transduction , Urinary Tract Infections/microbiology , Urinary Tract Infections/metabolism , Urinary Tract Infections/immunology , Uropathogenic Escherichia coli/immunology
20.
Arch Microbiol ; 206(8): 344, 2024 Jul 05.
Article in English | MEDLINE | ID: mdl-38967798

ABSTRACT

Uropathogenic Escherichia coli, the most common cause for urinary tract infections, forms biofilm enhancing its antibiotic resistance. To assess the effects of compounds on biofilm formation of uropathogenic Escherichia coli UMN026 strain, a high-throughput combination assay using resazurin followed by crystal violet staining was optimized for 384-well microplate. Optimized assay parameters included, for example, resazurin and crystal violet concentrations, and incubation time for readouts. For the assay validation, quality parameters Z' factor, coefficient of variation, signal-to-noise, and signal-to-background were calculated. Microplate uniformity, signal variability, edge well effects, and fold shift were also assessed. Finally, a screening with known antibacterial compounds was conducted to evaluate the assay performance. The best conditions found were achieved by using 12 µg/mL resazurin for 150 min and 0.023% crystal violet. This assay was able to detect compounds displaying antibiofilm activity against UMN026 strain at sub-inhibitory concentrations, in terms of metabolic activity and/or biomass.


Subject(s)
Anti-Bacterial Agents , Biofilms , Gentian Violet , High-Throughput Screening Assays , Oxazines , Uropathogenic Escherichia coli , Xanthenes , Biofilms/drug effects , Biofilms/growth & development , Uropathogenic Escherichia coli/drug effects , Uropathogenic Escherichia coli/physiology , High-Throughput Screening Assays/methods , Xanthenes/chemistry , Anti-Bacterial Agents/pharmacology , Gentian Violet/metabolism , Oxazines/pharmacology , Oxazines/metabolism , Oxazines/chemistry , Microbial Sensitivity Tests , Urinary Tract Infections/microbiology , Humans
SELECTION OF CITATIONS
SEARCH DETAIL